drugset
drugset / Trial / NCT06963320

Phase II Clinical Study of H001 Capsule in the Prevention of Venous Thromboembolism After Total Knee Arthroplasty

NCT06963320 ↗

Phase 2 Recruiting 320 enrolled Livzon Pharmaceutical Group Inc.
RandomizedParallel-groupOpen-labelTreatment

Summary

This study is a multicenter, randomized, open-label, positive-controlled Phase II clinical study to evaluate the efficacy and safety of H001 capsules in the prevention of venous thromboembolism (VTE) in subjects undergoing Total Knee Arthroplasty.

Timeline

Start
2025-01-20
Primary completion
2025-06-30
Completion
2025-07-30

Drugs

EvaluationDrugModalityDoseRoute
Comparator Enoxaparin sodium Other / unclassified 40 mg Subcutaneous
Subject H001 Unknown 200 mg Oral
Subject H001 Unknown 300 mg Oral

Indications

cardiovascular disorder